Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MBX Biosciences, Inc. (MBX)

MBX Biosciences Doses First Patient in Pivotal Phase 3 Canvuparatide Trial

Neutral Impact 3 of 5 product/contract Written later

MBX Biosciences said it has dosed the first patient in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for chronic hypoparathyroidism. The trial is planned to enroll approximately 160 adults and is a step toward potential registration of the drug candidate, though the filing reports no financial results or regulatory approval.

Key points

  • First patient dosed in the Phase 3 oPTimize trial, announced August 27, 2026
  • Trial plans to enroll approximately 160 adults, randomized 3:1 to canvuparatide or placebo over a 26-week double-blind period
  • Primary endpoint is a composite responder measure at Week 26, followed by a 78-week open-label extension
  • Trial is registered as NCT07699471 on clinicaltrials.gov

The filing

CompanyMBX Biosciences, Inc. (MBX)
Form8-K, current report
Filed with the SECAug 27, 2026, 8:34 AM ET
Accession number0001193125-26-369674

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.